Actelion announces commercial availability of Uptravi (selexipag) in Germany...
(Source: Actelion Ltd) Market authorization for treatment of pulmonary arterial hypertension granted by European Commission on 12 May 2016 Uptravi available for patients in Germany as of 15 June 2016...
View ArticleActelion announces US commercial availability of UPTRAVI (selexipag) as of 4...
(Source: Actelion Ltd) UPTRAVI - FDA approved on 21 December 2015 for treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization...
View ArticleActelion receives approval for Uptravi (selexipag) for the treatment of...
(Source: Actelion Ltd) Approval granted by Medsafe in New Zealand on 17 March 2016 and by the TGA in Australia on 18 March 2016 ALLSCHWIL, SWITZERLAND - 22 March 2016 - Actelion Ltd (SIX: ATLN)...
View ArticleActelion receives Health Canada approval for Uptravi (selexipag) for the...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 January 2016 - Actelion (SIX: ATLN) announced today that Health Canada has granted a Notice of Compliance (NOC) approving the orally active, selective...
View ArticleEisai Demonstrates Efficacy of Investigational Dual Orexin Receptor...
Presented at 53rd American College of Neuropsychopharmacology Annual Meeting Tokyo, Dec 10, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that...
View ArticleActelion is granted marketing authorization for Uptravi (selexipag) in...
(Source: Actelion Ltd) Marketing authorization granted by European Commission on 12 May 2016 First European Union (EU) market introduction to commence in the near future ALLSCHWIL, SWITZERLAND - 17 May...
View ArticleActelion delivers excellent results in the first quarter 2015 (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 April 2015- Actelion Ltd (SIX: ATLN) today announced its results for the first quarter of 2015. OPERATING HIGHLIGHTS Opsumit (macitentan) - Q1...
View ArticleActelion advances clinical development of its specialty immunology pipeline...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 April 2015 - Actelion Ltd (SIX: ATLN) announced today that it is accelerating its clinical development efforts in the field of immunological...
View ArticleActelion receives positive CHMP opinion for Uptravi (selexipag) for the...
(Source: Actelion Ltd) The European Commission is expected to make a final decision within 67 days. ALLSCHWIL, SWITZERLAND - 29 January 2016 - Actelion (SIX: ATLN) announced today that the Committee...
View ArticleDesperately Seeking Shut-Eye
In the early 1970s, a colleague of Stanford Universityās William Dement remarked on the resemblance of a narcolepsy patientās symptoms to those of a recent canine patient he had read about. The...
View ArticleActelion receives US FDA approval of Uptravi (selexipag) for the treatment of...
(Source: Actelion Ltd) Uptravi approved for treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression and reduce the risk of hospitalization for PAH Uptravi will be...
View ArticleSelexipag (Uptravi) data in pulmonary arterial hypertension to be presented...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 02 March 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III selexipag (UptraviĀ®) study will be shared during an...
View ArticleActelion delivers excellent first half 2015 results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2015- Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2015. OPERATING HIGHLIGHTS OpsumitĀ® - Sales of CHF...
View ArticleActelion's New Drug Application for selexipag (Uptravi) is accepted by the US...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 03 March 2015 - Actelion Ltd (SIX: ATLN) today announced the formal acceptance of the New Drug Application (NDA) for selexipag (UptraviĀ®) by the US Food...
View ArticleActelion submits selexipag (Uptravi) for EMA Marketing Authorisation in...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 02 December 2014 - Actelion Ltd (SIX: ATLN) today announced the submission of a centralized Marketing Authorisation Application (MAA) to the European...
View ArticleVery strong performance continues in the first quarter of 2016 - driven by...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 April 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first three months of 2016. OPERATING HIGHLIGHTS Excellent Opsumit...
View ArticleSelexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 16 June 2014 - Actelion Ltd (SIX: ATLN) today announced the top-line results of the pivotal Phase III GRIPHON study in 1,156 patients with pulmonary...
View ArticleActelion submits US FDA New Drug Application for selexipag (Uptravi) in...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 December 2014 - Actelion Ltd (SIX: ATLN) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration...
View ArticleActelion initiates Phase III study to evaluate macitentan (Opsumit) in...
(Source: Actelion Ltd) Phase III study TOMORROW aims to show the long-term benefits of macitentan (Opsumit) in children with pulmonary arterial hypertension (PAH) Global program has received...
View ArticleActelion delivers strong nine months results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 20 October 2015 - Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2015. OPERATING HIGHLIGHTS Opsumit (macitentan)...
View Article